Based on the pivotal mechanism of the NIP30/REGγ/TRAF6 axis, we defined that the CKII inhibitor TTP22 could alleviate osteoporosis by promoting the ubiquitin-independent proteasomal degradation of TRAF6 and provided a strategy for the treatment of osteoporosis. Here, TRAF6 is linked to osteoporosis.